Curly Morris
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Curly Morris has a total of 162 co-authors. Here are the top co-authors by number of shared publications:
Anja van Biezen
European Society for Blood and Marrow Transplantation, Leiden, The Netherlands
4 shared publicationsGordon Cook
Leeds Cancer Centre St. James University Hospital Leeds UK
3 shared publicationsMary Drake
Haematology Department Belfast City Hospital Belfast UK
3 shared publicationsMatthew Streetly
Guy’s and St. Thomas’ Hospital NHS Foundation Trust London UK
3 shared publicationsRakesh Popat
University College London Hospitals NHS Foundation Trust London UK
3 shared publicationsSimona Iacobelli
University Tor Vergata, Rome, Italy
3 shared publications
Latest Publications
- Open Access
What can we do about patients presenting with myeloma and severe renal failure? Observations from the UK MERIT plasma exchange trial
Myeloma patients presenting with renal failure continue to have a poor prognosis despite significant advances in anti-myeloma therapy. MERIT was a randomised clinical trial (RCT), set up to evaluate if mechanical reduction of elevated free light chain levels (FLC) would result in clinical benefit. Completion of the planned seven plasma exchanges (PEs) in the first 14 days failed to show, for the exchange group, a greater reduction in FLC or any improvement in dialysis independence at 100 days or subsequently. To improve prognosis for these patients requires earlier diagnosis and prompt anti-myeloma therapy with effectiveness guided by frequent FLC monitoring.
Open AccessWhat can we do about patients presenting with myeloma and severe renal failure? Observations from the UK MERIT plasma exchange trial
Myeloma patients presenting with renal failure continue to have a poor prognosis despite significant advances in anti-myeloma therapy. MERIT was a randomised clinical trial (RCT), set up to evaluate if mechanical reduction of elevated free light chain levels (FLC) would result in clinical benefit. Completion of the planned seven plasma exchanges (PEs) in the first 14 days failed to show, for the exchange group, a greater reduction in FLC or any improvement in dialysis independence at 100 days or subsequently. To improve prognosis for these patients requires earlier diagnosis and prompt anti-myeloma therapy with effectiveness guided by frequent FLC monitoring.
- Open Access
- 20 June 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (12) , 3541
Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study
Background: The main goal of this post hoc analysis of the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study was to evaluate the rate of short- and long-term infectious and non-infectious complications occurring after ASCT in patients with multiple myeloma (MM). Methods: The analysis included all patients with MM from the CALM study who underwent ≥1 ASCT. The primary endpoint of the analysis was to determine the rate of infectious and non-infectious complications after ASCT and to compare them in three time periods: 0–100 days, 101 days–1 year, and >1 year after the first transplant. Results: The analysis included a total of 3552 patients followed up for a median of 56.7 months (range 0.4–108.1). Complication rates decreased with the time from ASCT with 24.85 cases per 100 patient-years from day 0 to 100 days after the transplant, and <2.31 cases per 100 patient-years from the 101st day. At 100 days after ASC T, 45.7% of patients had complications, with infectious events being twice as frequent as non-infectious complications. Bacterial infections (6.5 cases per 100 patient-years, 95% CI: 6.1–7.0) and gastrointestinal complications (4.7 cases per 100 patient-years, 95% CI: 4.3–5.1) were the most common early events. The pattern of complications changed with time from ASCT. The presence of complications after ASCT was not associated with overall survival. Conclusions: Our data provide a solid basis for comparing ASCT-related complications to those caused by emerging treatments in multiple myeloma, such as CAR T-cell therapy and other immunotherapies.
- 20 June 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (12) , 3541
Open AccessComplications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study
Background: The main goal of this post hoc analysis of the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study was to evaluate the rate of short- and long-term infectious and non-infectious complications occurring after ASCT in patients with multiple myeloma (MM). Methods: The analysis included all patients with MM from the CALM study who underwent ≥1 ASCT. The primary endpoint of the analysis was to determine the rate of infectious and non-infectious complications after ASCT and to compare them in three time periods: 0–100 days, 101 days–1 year, and >1 year after the first transplant. Results: The analysis included a total of 3552 patients followed up for a median of 56.7 months (range 0.4–108.1). Complication rates decreased with the time from ASCT with 24.85 cases per 100 patient-years from day 0 to 100 days after the transplant, and <2.31 cases per 100 patient-years from the 101st day. At 100 days after ASC T, 45.7% of patients had complications, with infectious events being twice as frequent as non-infectious complications. Bacterial infections (6.5 cases per 100 patient-years, 95% CI: 6.1–7.0) and gastrointestinal complications (4.7 cases per 100 patient-years, 95% CI: 4.3–5.1) were the most common early events. The pattern of complications changed with time from ASCT. The presence of complications after ASCT was not associated with overall survival. Conclusions: Our data provide a solid basis for comparing ASCT-related complications to those caused by emerging treatments in multiple myeloma, such as CAR T-cell therapy and other immunotherapies.
- Open Access
- 11 October 2021
- Published by Wiley in British Journal of Haematology
- Vol. 196 (4) , E33-E37
Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial
- 11 October 2021
- Published by Wiley in British Journal of Haematology
- Vol. 196 (4) , E33-E37
Open AccessOutcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial
- Open Access
- 14 March 2021
- Published by Wiley in British Journal of Haematology
- Vol. 193 (3) , E19-E22
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial
- 14 March 2021
- Published by Wiley in British Journal of Haematology
- Vol. 193 (3) , E19-E22
Open AccessUsing depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial
- Open Access
- 1 January 2021
- Published by SAABRON PRESS in Clinical Hematology International
- Vol. 3 (1) , 27-33
How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma
When the bortezomib [PS341], adriamycin and dexamethasone (PAD) regimen was first evaluated, the response rate in untreated patients was much superior to that elicited by conventional chemotherapeutic agents. We demonstrated the efficacy of PAD in relapsed or refractory patients by comparing the response rate obtained in 53 patients who received vincristine, adriamycin and dexamethasone (VAD) or equivalent regimen as induction therapy, using a comparative design in which each patient acted as their own control. Whereas 25 patients had a positive response to VAD, 37 patients had a response to PAD ≤ partial remission (PR) (p = 0.023). Using the more stringent response level of very good PR (VGPR) the results favored the PAD regimen very significantly (p = 0.006) (McNemars test). Similar results were seen using paired M-protein levels from individual patient comparisons. As the PAD regimen was subsequently adopted as the re-induction therapy in the British Society for Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) trial, now concluded, we have retrospectively analyzed the findings from both studies. Comparison of response rates and adverse effects of patients having had previous autologous transplantation (Cohort 1) with the corresponding data from Myeloma X showed close correlation. These findings provide evidence that rapid results may be obtained in the evaluation of newly introduced, and potentially highly effective, anti-tumour agents by direct comparison to the response to the immediately preceding standard regimen, particularly in relatively resistant tumours.
- 1 January 2021
- Published by SAABRON PRESS in Clinical Hematology International
- Vol. 3 (1) , 27-33
Open AccessHow to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma
When the bortezomib [PS341], adriamycin and dexamethasone (PAD) regimen was first evaluated, the response rate in untreated patients was much superior to that elicited by conventional chemotherapeutic agents. We demonstrated the efficacy of PAD in relapsed or refractory patients by comparing the response rate obtained in 53 patients who received vincristine, adriamycin and dexamethasone (VAD) or equivalent regimen as induction therapy, using a comparative design in which each patient acted as their own control. Whereas 25 patients had a positive response to VAD, 37 patients had a response to PAD ≤ partial remission (PR) (p = 0.023). Using the more stringent response level of very good PR (VGPR) the results favored the PAD regimen very significantly (p = 0.006) (McNemars test). Similar results were seen using paired M-protein levels from individual patient comparisons. As the PAD regimen was subsequently adopted as the re-induction therapy in the British Society for Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) trial, now concluded, we have retrospectively analyzed the findings from both studies. Comparison of response rates and adverse effects of patients having had previous autologous transplantation (Cohort 1) with the corresponding data from Myeloma X showed close correlation. These findings provide evidence that rapid results may be obtained in the evaluation of newly introduced, and potentially highly effective, anti-tumour agents by direct comparison to the response to the immediately preceding standard regimen, particularly in relatively resistant tumours.
- Open Access
- 18 September 2019
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 55 (2) , 356-366
Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor
Plerixafor plus granulocyte-colony stimulating factor (G-CSF) enhances the mobilization of hematopoietic stem cells (HSCs) for collection and subsequent autologous hematopoietic stem cell transplantation (HSCT) in patients with multiple myeloma (MM). This international, multicenter, noninterventional registry study (NCT01362972), evaluated long-term outcomes for MM patients who received plerixafor versus other mobilization regimens. The comparisons were: G-CSF + plerixafor (G-CSF + P) versus G-CSF-; G-CSF + P versus G-CSF + chemotherapy (G-CSF + C); and G-CSF + P + C versus G-CSF + C. Propensity score matching was used to balance groups. Primary outcome measures were progression free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR) after transplantation. After propensity matching, 77 versus 41 patients in the G-CSF + P versus G-CSF cohorts, 129 versus 129 in the G-CSF + P versus G-CSF + C cohorts, and 117 versus 117 in the G-CSF + P + C versus G-CSF + C cohorts were matched, respectively. Propensity score matching resulted in a smaller sample size and imbalances were not completely overcome. For both PFS and OS, the upper limits of the hazard ratio 95% confidence intervals exceeded prespecified boundaries; noninferiority was not demonstrated. CIR rates were higher in the plerixafor cohorts. G-CSF + P remains an option for the mobilization of HSCs in poor mobilizers with MM with no substantial differences in PFS, OS, and CIR in comparison with other regimens.
- 18 September 2019
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 55 (2) , 356-366
Open AccessResults from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor
Plerixafor plus granulocyte-colony stimulating factor (G-CSF) enhances the mobilization of hematopoietic stem cells (HSCs) for collection and subsequent autologous hematopoietic stem cell transplantation (HSCT) in patients with multiple myeloma (MM). This international, multicenter, noninterventional registry study (NCT01362972), evaluated long-term outcomes for MM patients who received plerixafor versus other mobilization regimens. The comparisons were: G-CSF + plerixafor (G-CSF + P) versus G-CSF-; G-CSF + P versus G-CSF + chemotherapy (G-CSF + C); and G-CSF + P + C versus G-CSF + C. Propensity score matching was used to balance groups. Primary outcome measures were progression free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR) after transplantation. After propensity matching, 77 versus 41 patients in the G-CSF + P versus G-CSF cohorts, 129 versus 129 in the G-CSF + P versus G-CSF + C cohorts, and 117 versus 117 in the G-CSF + P + C versus G-CSF + C cohorts were matched, respectively. Propensity score matching resulted in a smaller sample size and imbalances were not completely overcome. For both PFS and OS, the upper limits of the hazard ratio 95% confidence intervals exceeded prespecified boundaries; noninferiority was not demonstrated. CIR rates were higher in the plerixafor cohorts. G-CSF + P remains an option for the mobilization of HSCs in poor mobilizers with MM with no substantial differences in PFS, OS, and CIR in comparison with other regimens.
- Open Access
- 1 June 2015
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 21 (6) , 1054-1058
Efficacy and Outcome of Allogeneic Transplantation in IgD and Nonsecretory Myeloma. A Report on Behalf of the Myeloma Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation
- 1 June 2015
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 21 (6) , 1054-1058
Open AccessEfficacy and Outcome of Allogeneic Transplantation in IgD and Nonsecretory Myeloma. A Report on Behalf of the Myeloma Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation
- 26 June 2014
- Published by Wiley in Transfusion
- Vol. 54 (10) , 2514-2522
Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide
Background: Dimethyl sulfoxide (DMSO) is essential for the preservation of liquid nitrogen–frozen stem cells, but is associated with toxicity in the transplant recipient.Study Design and Methods: In this prospective noninterventional study, we describe the use of DMSO in 64 European Blood and Marrow Transplant Group centers undertaking autologous transplantation on patients with myeloma and lymphoma and analyze side effects after return of DMSO‐preserved stem cells.Results: While the majority of centers continue to use 10% DMSO, a significant proportion either use lower concentrations, mostly 5 or 7.5%, or wash cells before infusion (some for selected patients only). In contrast, the median dose of DMSO given (20 mL) was much less than the upper limit set by the same institutions (70 mL). In an accompanying statistical analysis of side effects noted after return of DMSO‐preserved stem cells, we show that patients in the highest quartile receiving DMSO (mL and mL/kg body weight) had significantly more side effects attributed to DMSO, although this effect was not observed if DMSO was calculated as mL/min. Dividing the myeloma and lymphoma patients each into two equal groups by age we were able to confirm this result in all but young myeloma patients in whom an inversion of the odds ratio was seen, possibly related to the higher dose of melphalan received by young myeloma patients.Conclusion: We suggest better standardization of preservation method with reduced DMSO concentration and attention to the dose of DMSO received by patients could help reduce the toxicity and morbidity of the transplant procedure.
- 26 June 2014
- Published by Wiley in Transfusion
- Vol. 54 (10) , 2514-2522
Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide
Background: Dimethyl sulfoxide (DMSO) is essential for the preservation of liquid nitrogen–frozen stem cells, but is associated with toxicity in the transplant recipient.Study Design and Methods: In this prospective noninterventional study, we describe the use of DMSO in 64 European Blood and Marrow Transplant Group centers undertaking autologous transplantation on patients with myeloma and lymphoma and analyze side effects after return of DMSO‐preserved stem cells.Results: While the majority of centers continue to use 10% DMSO, a significant proportion either use lower concentrations, mostly 5 or 7.5%, or wash cells before infusion (some for selected patients only). In contrast, the median dose of DMSO given (20 mL) was much less than the upper limit set by the same institutions (70 mL). In an accompanying statistical analysis of side effects noted after return of DMSO‐preserved stem cells, we show that patients in the highest quartile receiving DMSO (mL and mL/kg body weight) had significantly more side effects attributed to DMSO, although this effect was not observed if DMSO was calculated as mL/min. Dividing the myeloma and lymphoma patients each into two equal groups by age we were able to confirm this result in all but young myeloma patients in whom an inversion of the odds ratio was seen, possibly related to the higher dose of melphalan received by young myeloma patients.Conclusion: We suggest better standardization of preservation method with reduced DMSO concentration and attention to the dose of DMSO received by patients could help reduce the toxicity and morbidity of the transplant procedure.
- Open Access
- 18 November 2011
- Published by American Society of Hematology in Blood
- Vol. 118 (21) , 2008
Has Allogeneic Transplantation a Role in the Management of Plasma Cell Leukaemia? A Study on Behalf of the Myeloma Subcomittee of the Chronic Leukaemia Working Party of the EBMT
Abstract 2008 We have previously reported a dismal outcome for patients with Plasma Cell Leukaemia (PCL) undergoing autologous transplantation, although such patients represent the younger and fittest with this condition and show superior survival to reports of non transplant patients. In this study we report two analyses of 85 eligible patients with PCL who received an allogeneic transplantation (Allo) between 1984 and 2009 and 411 patients receiving autologous transplantation (Auto) in the same period and a further comparison with 850 (Allo) myeloma MM.The first analysis was restricted to the years 1998 to 2009 allowing the identification of a large Myeloablative (MAC) population (n=45) and a smaller reduced intensity (n=17) conditioning (RIC) group. On account of the number of comparisons in the study and the size of the sub populations, only statistically highly significant differences are reported; less significantly powerful differences are viewed as a trend. Patients treated with MAC and RIC were essentially similar although significantly younger (45.9 and 52.9 yrs respectively) than the Auto patients (55.9 yrs) at the time of diagnosis, with similar differences at the time of transplant. RIC patients had a longer time (10.2 months) to transplant than the MAC (6.0m) and Auto (5.8m) groups. No difference was seen in rates of engraftment, acute or chronic graft versus host disease. MAC patients had a higher Complete Response (CR) than Auto. Progression Free Survival (PFS) at 12 and 60 months respectively (with Confidence Intervals) was as follows: Auto; 0.51 (0.45 – 0.57) and 0.10 (0.06 – 0.15), MAC; 0.39 (0.26 – 0.57) and 0.19 (0.09 – 0.39), RIC; 0.43 (0.23 – 0.80) and 0.11 (0.02 – 0.67) with the MAC and RIC curves possibly crossing the Auto curve between 2 and 4 years. These differences are due to highly significant differences in Non Relapse Mortality (Auto better) and Progression (Auto worse) This translates into Overall Survival (OS) at similar times (12 and 60 months) to PFS as follows: Auto; 0.73 (0.68 – 0.78) and 0.25 (0.19 – 0.33), MAC; 0.46 (0.33 – 0.65) and 0.27 (0.16 – 0.47), RIC; 0.59 (0.38 – 0.91) and 0.19 (0.04 – 0.93). The differences between MAC and RIC were not statistically significant. It was noted that whereas Auto patients continue to relapse with time there is a (small) plateau of survivors in both MAC and RIC. These findings are confirmed in the larger non selected analysis of all Auto and Allo patients Although age is seen as a strong prognostic factor favouring the Allo patients appropriate adjustment was made in the analysis. In the comparison of Allo in PCL v. MM the PFS and OS for PCL was inferior to MM: Data at 48 months for PFS and OS respectively: MM 0.22 (0.19 – 0.26) and 0.44 (0.40 – 0.48), PCL 0.20 (0.10 – 0.41) and 0.32 (0.19 – 0.53). In all three analyses the PCL Allo group shows a clear plateau at about 0.2 (20%) similar that seen in a number of recent studies of Allo transplantation in MM, but at a lower level. This contrasts with the ongoing attrition of patients experiencing progression in Auto transplantation. This study presents the first major analysis of Allo transplantation in PCL, confirms the poor prognosis with all types of transplant therapy while indicating it remains the best option for patients with PCL. Further improvements in the management of NRM can improve the outcome for these patients.
- 18 November 2011
- Published by American Society of Hematology in Blood
- Vol. 118 (21) , 2008
Open AccessHas Allogeneic Transplantation a Role in the Management of Plasma Cell Leukaemia? A Study on Behalf of the Myeloma Subcomittee of the Chronic Leukaemia Working Party of the EBMT
Abstract 2008 We have previously reported a dismal outcome for patients with Plasma Cell Leukaemia (PCL) undergoing autologous transplantation, although such patients represent the younger and fittest with this condition and show superior survival to reports of non transplant patients. In this study we report two analyses of 85 eligible patients with PCL who received an allogeneic transplantation (Allo) between 1984 and 2009 and 411 patients receiving autologous transplantation (Auto) in the same period and a further comparison with 850 (Allo) myeloma MM.The first analysis was restricted to the years 1998 to 2009 allowing the identification of a large Myeloablative (MAC) population (n=45) and a smaller reduced intensity (n=17) conditioning (RIC) group. On account of the number of comparisons in the study and the size of the sub populations, only statistically highly significant differences are reported; less significantly powerful differences are viewed as a trend. Patients treated with MAC and RIC were essentially similar although significantly younger (45.9 and 52.9 yrs respectively) than the Auto patients (55.9 yrs) at the time of diagnosis, with similar differences at the time of transplant. RIC patients had a longer time (10.2 months) to transplant than the MAC (6.0m) and Auto (5.8m) groups. No difference was seen in rates of engraftment, acute or chronic graft versus host disease. MAC patients had a higher Complete Response (CR) than Auto. Progression Free Survival (PFS) at 12 and 60 months respectively (with Confidence Intervals) was as follows: Auto; 0.51 (0.45 – 0.57) and 0.10 (0.06 – 0.15), MAC; 0.39 (0.26 – 0.57) and 0.19 (0.09 – 0.39), RIC; 0.43 (0.23 – 0.80) and 0.11 (0.02 – 0.67) with the MAC and RIC curves possibly crossing the Auto curve between 2 and 4 years. These differences are due to highly significant differences in Non Relapse Mortality (Auto better) and Progression (Auto worse) This translates into Overall Survival (OS) at similar times (12 and 60 months) to PFS as follows: Auto; 0.73 (0.68 – 0.78) and 0.25 (0.19 – 0.33), MAC; 0.46 (0.33 – 0.65) and 0.27 (0.16 – 0.47), RIC; 0.59 (0.38 – 0.91) and 0.19 (0.04 – 0.93). The differences between MAC and RIC were not statistically significant. It was noted that whereas Auto patients continue to relapse with time there is a (small) plateau of survivors in both MAC and RIC. These findings are confirmed in the larger non selected analysis of all Auto and Allo patients Although age is seen as a strong prognostic factor favouring the Allo patients appropriate adjustment was made in the analysis. In the comparison of Allo in PCL v. MM the PFS and OS for PCL was inferior to MM: Data at 48 months for PFS and OS respectively: MM 0.22 (0.19 – 0.26) and 0.44 (0.40 – 0.48), PCL 0.20 (0.10 – 0.41) and 0.32 (0.19 – 0.53). In all three analyses the PCL Allo group shows a clear plateau at about 0.2 (20%) similar that seen in a number of recent studies of Allo transplantation in MM, but at a lower level. This contrasts with the ongoing attrition of patients experiencing progression in Auto transplantation. This study presents the first major analysis of Allo transplantation in PCL, confirms the poor prognosis with all types of transplant therapy while indicating it remains the best option for patients with PCL. Further improvements in the management of NRM can improve the outcome for these patients.
- Open Access
- 31 January 2011
- Published by Wiley in British Journal of Haematology
- Vol. 153 (5) , 666-668
Re-transplantation after bortezomib-based therapy
- 31 January 2011
- Published by Wiley in British Journal of Haematology
- Vol. 153 (5) , 666-668
Open AccessRe-transplantation after bortezomib-based therapy